{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:50:36Z","timestamp":1791827436129,"version":"4.3.4"},"reference-count":23,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"unspecified","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,9,23]]},"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1136\/bmjopen-2026-122906","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:25:26Z","timestamp":1791825926000},"page":"e122906","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Healthcare resource utilisation and costs of chemotherapy and autologous haemopoietic cell transplantation of patients with multiple myeloma in China: a multi-centre retrospective analysis"],"prefix":"10.1136","volume":"16","author":[{"given":"Yannan","family":"Wang","sequence":"first","affiliation":[{"name":"Center for Clinical Pharmacy, Cancer Center, I Phrase Clinical Trials Ward, Zhejiang Provincial People's Hospital(Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuicui","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiquan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Urology Surgery, Ningbo Yinzhou No 2 Hospital, Ningbo, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijia","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5849-2342","authenticated-orcid":false,"given":"Di","family":"Pan","sequence":"additional","affiliation":[{"name":"Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"2026101210251828000_16.10.e122906.1","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026101210251828000_16.10.e122906.2","first-page":"373","article-title":"Multiple Myeloma: Diagnosis and Treatment","volume":"95","author":"Michels","year":"2017","journal-title":"Am Fam Physician"},{"key":"2026101210251828000_16.10.e122906.3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clml.2019.09.621","article-title":"Treatment Options for Triple-class Refractory Multiple Myeloma","volume":"20","author":"Mikhael","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026101210251828000_16.10.e122906.4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40265-017-0841-y","article-title":"Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update","volume":"78","author":"Nijhof","year":"2018","journal-title":"Drugs"},{"key":"2026101210251828000_16.10.e122906.5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2015.10.014","article-title":"SnapShot: Multiple Myeloma","volume":"28","author":"Braggio","year":"2015","journal-title":"Cancer Cell"},{"key":"2026101210251828000_16.10.e122906.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4177"},{"key":"2026101210251828000_16.10.e122906.7","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313"},{"key":"2026101210251828000_16.10.e122906.8","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.6004\/jnccn.2023.0061","article-title":"Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Kumar","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"2026101210251828000_16.10.e122906.9","unstructured":"Financial burden of cancer care . National cancer institute cancer trends progress report. Available: https:\/\/ progr essre port. cancer. gov\/ after\/ econo mic_ burden"},{"key":"2026101210251828000_16.10.e122906.10","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1080\/10245332.2015.1122259","article-title":"Real-world outcome and healthcare costs of relapsed or refractory multiple myeloma: A retrospective analysis from the Chinese experience","volume":"21","author":"Zhou","year":"2016","journal-title":"Hematology"},{"key":"2026101210251828000_16.10.e122906.11","unstructured":"Ministry of Human Resources and Social Security of the People\u2019s of China . Ministry of human resources and social security releases results of negotiations on national reimbursement drug list entry 2017. 2017. Available: https:\/\/www.mohrss.gov.cn\/SYrlzyhshbzb\/shehuibaozhang\/zcwj\/201707\/t20170718_274153.html [Accessed 19 Oct 2025]."},{"key":"2026101210251828000_16.10.e122906.12","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-021-06698-5","article-title":"The impacts of Chinese drug volume-based procurement policy on the use of policy-related antibiotic drugs in Shenzhen, 2018-2019: an interrupted time-series analysis","volume":"21","author":"Yang","year":"2021","journal-title":"BMC Health Serv Res"},{"key":"2026101210251828000_16.10.e122906.13","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jtct.2022.03.021","article-title":"Health Care Resource Utilization and Total Costs of Care Among Patients with Diffuse Large B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy in the United States","volume":"28","author":"Keating","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2026101210251828000_16.10.e122906.14","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s41669-022-00344-4","article-title":"Healthcare Resource Utilization and Cost of Patients with Multiple Myeloma in Germany: A Retrospective Claims Data Analysis","volume":"6","author":"Kocaata","year":"2022","journal-title":"Pharmacoecon Open"},{"key":"2026101210251828000_16.10.e122906.15","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.clinthera.2019.01.009","article-title":"Cost Offsets in the Treatment Journeys of Patients With Relapsed\/Refractory Multiple Myeloma","volume":"41","author":"Ailawadhi","year":"2019","journal-title":"Clin Ther"},{"key":"2026101210251828000_16.10.e122906.16","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1185\/03007995.2015.1031732","article-title":"Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma","volume":"31","author":"Arikian","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"2026101210251828000_16.10.e122906.17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"2026101210251828000_16.10.e122906.18","doi-asserted-by":"crossref","unstructured":"Zhu H , Zhu J , Zhou Y , et al . n.d. Impact of the National Reimbursement Drug List Negotiation Policy on Accessibility of Anticancer Drugs in China: An Interrupted Time Series Study. Front Public Health 10:1093. doi:10.3389\/fpubh.2022.921093","DOI":"10.3389\/fpubh.2022.921093"},{"key":"2026101210251828000_16.10.e122906.19","doi-asserted-by":"crossref","first-page":"1593099","DOI":"10.3389\/fphar.2025.1593099","article-title":"Effects of national volume-based procurement policy on the usage and expenditure of platinum antineoplastic drugs in China: an interrupted time series study","volume":"16","author":"Yu","year":"2025","journal-title":"Front Pharmacol"},{"key":"2026101210251828000_16.10.e122906.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611750"},{"key":"2026101210251828000_16.10.e122906.21","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2020-134538","article-title":"Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial","volume":"136","author":"Perrot","year":"2020","journal-title":"Blood"},{"key":"2026101210251828000_16.10.e122906.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204925"},{"key":"2026101210251828000_16.10.e122906.23","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1080\/14737167.2025.2461636","article-title":"Autologous stem-cell transplantation and maintenance therapy for transplant-eligible multiple myeloma patients: cost-effectiveness analysis based on a network meta-analysis","volume":"25","author":"Wu","year":"2025","journal-title":"Expert Rev Pharmacoecon Outcomes Res"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-122906","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:25:28Z","timestamp":1791825928000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-122906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":23,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,12]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1136\/bmjopen-2026-122906"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-122906","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}